A phase II clinical trial (NCT04847466) is evaluating the effectiveness of irradiated PD-L1 CAR-haNK cells in combination with the PD-1 inhibitor pembrolizumab plus N-803 (ALT-803, an IL-15 agonist) in patients with recurrent or metastatic gastric cancer and HNSCC. This evidence concerns the gene CD274 and head and neck squamous cell carcinoma.